Durable response to afatinib in advanced lung adenocarcinoma harboring a novel NPTN-NRG1 fusion: a case report

World Journal of Surgical Oncology

Case Report

Wendy Wu¹  Xiaoxing Su¹  Chenhui Song¹  Yan Lei¹  Hui Li¹  Lin Li²  Xin Nie²  Gang Cheng²  Di Ma²  Ping Zhang²  Zhixin Bie³  Di Cui⁴  Min Zhang⁵ 

[1]Berry Oncology Corporation, No. 4 Science Park Road, 102206, Beijing, China

[2]Department of Medical Oncology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, No. 1 DaHua Road, 100730, Beijing, China

[3]Department of Minimally Invasive Tumor Therapies Center, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China

[4]Department of Pathology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China

[5]Department of Radiology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China

关键词: NRG1 fusion;    Afatinib;    Lung cancer;    Next-generation sequencing (NGS);   

DOI  :  10.1186/s12957-023-03129-z

 received in 2023-05-09, accepted in 2023-07-29,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundNRG1 fusions are rare oncogenic drivers in solid tumors, and the incidence of NRG1 fusions in non-small cell lung cancer (NSCLC) was 0.26%. It is essential to explore potential therapeutic strategies and efficacy predictors for NRG1 fusion-positive cancers.Case presentationWe report an advanced lung adenocarcinoma patient harboring a novel NPTN-NRG1 fusion identified by RNA-based next-generation sequencing (NGS), which was not detected by DNA-based NGS at initial diagnosis. Transcriptomics data of the tissue biopsy showed NRG1α isoform accounted for 30% of total NRG1 reads, and NRG1β isoform was undetectable. The patient received afatinib as fourth-line treatment and received a progression-free survival (PFS) of 14 months.ConclusionsThis report supports afatinib can provide potential benefit for NRG1 fusion patients, and RNA-based NGS is an accurate and cost-effective strategy for fusion detection and isoform identification.

【 授权许可】

CC BY   
© BioMed Central Ltd., part of Springer Nature 2023

【 图 表 】

Fig. 3

Fig. 2

40517_2023_266_Article_IEq54.gif